ArticleCancer immunology, immunotherapy : CII2012
HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response.
Article in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Infiltration to infection: key virulence players of Helicobacter pylori pathogenicity.Infection · 2024Pooled it
- Article
- Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer.Journal of translational medicine · 2025Review
- Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.Journal of experimental & clinical cancer research : CR · 2024Review
- Role of Helicobacter pylori virulence factors and alteration of the Tumor Immune Microenvironment: challenges and opportunities for Cancer Immunotherapy.Archives of microbiology · 2024Review
- Strategies for Overcoming Immune Evasion in Bladder Cancer.International journal of molecular sciences · 2024Review
- Special Issue "Bacterial Toxins and Cancer".International journal of molecular sciences · 2024Article
- Neutrophil-activating protein inFrontiers in immunology · 2024Article
- Outer Membrane Vesicles (OMVs) as Biomedical Tools and Their Relevance as Immune-Modulating Agents againstInternational journal of molecular sciences · 2023Review
- The Role ofInternational journal of molecular sciences · 2022Review
- CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.Nature biomedical engineering · 2022Article
- Macrophage-Mediated Melanoma Reduction after HP-NAP Treatment in a Zebrafish Xenograft Model.International journal of molecular sciences · 2022Article
- Effects ofFrontiers in immunology · 2022Review
- HP-NAP ofFrontiers in immunology · 2022Review
- Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).Oncology reports · 2021Review
- Germline mutations and blood malignancy (Review).Oncology reports · 2021Review
- Review
- PositiveOncotarget · 2017Article
- One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode.Journal of visualized experiments : JoVE · 2016Article
- Future directions in bladder cancer immunotherapy: towards adaptive immunity.Immunotherapy · 2016Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravesical Bacillus Calmette-Guérin (BCG) is the gold standard treatment for intermediate and high-risk non-muscle-invasive bladder cancer. BCG therapy is the most successful example of immunotherapy in cancer. Unfortunately, the treatment-related side effects are still relevant. Furthermore, non-responder patients are candidate to radical cystectomy in the absence of valuable alternative options. These aspects have prompted the search for newer biological response modifiers (BRM) with a better benefit/side effects ratio. The toll-like receptor (TLR) 2 ligand, Helicobacter pylori protein HP-NAP, has been shown to deserve a potential role as BRM. HP-NAP is capable of driving the differentiation of T helper (Th) 1 cells, both in vitro and in vivo, because of its ability to create an IL-12-enriched milieu. Herein, we report that local administration of HP-NAP decreases tumour growth by triggering tumour necrosis in a mouse model of bladder cancer implant. The effect is accompanied by a significant accumulation of both CD4+ and CD8+ IFN-γ-secreting cells, within tumour and regional lymph nodes. Noteworthy, HP-NAP-treated tumours show also a reduced vascularization due to the anti-angiogenic activity of IFN-γ induced by HP-NAP. Our findings strongly indicate that HP-NAP might become a novel therapeutic "bullet" for the cure of bladder tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.